文献速递临床试验与 GCP流行病学与生物统计医学人工智能与信息学

胶囊海绵生物标志物风险分层在巴雷特食管监测中的前瞻性评估:英国真实世界实施

Biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation.
PubMed 文献 · Lancet · 2025-06-23

研究纳入英国13家医院910例非异型增生巴雷特食管患者,采用胶囊海绵联合生物标志物进行风险分层。高风险组任何异型增生或更严重病变的阳性预测值为37.7%,低风险组高级别异型增生或癌的患病率为0.4%。作者认为该风险分层可富集异型增生,低风险巴雷特食管或可用胶囊海绵监测替代内镜。

要点

  • 910例患者中高风险138例(15%)、中风险283例(31%)、低风险489例(54%)。
  • 高风险组任何异型增生或更严重病变的阳性预测值为37.7%(95%CI 29.7-46.4)。
  • 低风险组高级别异型增生或癌的患病率为0.4%(95%CI 0.1-1.6)。

核心结论

  • 风险分层面板可显著富集异型增生,基于胶囊海绵的监测或可用于低风险巴雷特食管以替代内镜。

研究设计与样本

  • 两项多中心、前瞻性、实用性实施研究,自英国13家医院招募至少18岁、末次内镜诊断为非异型增生巴雷特食管并按已发表英国指南接受监测的患者,共910例,于2020年8月至2024年12月入组。
  • 患者接受胶囊海绵检测并在ISO认证实验室评估,依据临床和胶囊海绵生物标志物分为低风险(临床和胶囊海绵生物标志物均阴性)、中风险(胶囊海绵生物标志物阴性、临床生物标志物阳性——年龄、性别和段长)和高风险(p53异常或腺体异型性,不论临床生物标志物如何,或两者兼有)。
  • 主要结局为根据风险分组诊断的需要治疗的高级别异型增生或癌。

主要发现

  • 910例中高风险138例(15%)、中风险283例(31%)、低风险489例(54%)。
  • 高风险组任何异型增生或更严重病变的阳性预测值为37.7%(95%CI 29.7-46.4)。
  • 同时具有异型性和p53异常的患者高级别异型增生或癌风险最高,相对低风险组的相对风险为135.8(95%CI 32.7-564.0)。
  • 低风险组高级别异型增生或癌的患病率为0.4%(95%CI 0.1-1.6);任何异型增生或癌的阴性预测值为97.8%(95%CI 95.9-98.8)。
  • 在数字病理工作流程中应用机器学习算法可将需要p53病理复核的比例降至32%,且未遗漏任何阳性病例。

关键数值与推荐

  • 低风险:临床和胶囊海绵生物标志物均阴性。
  • 中风险:胶囊海绵生物标志物阴性,临床生物标志物(年龄、性别和段长)阳性。
  • 高风险:p53异常或腺体异型性,不论临床生物标志物如何,或两者兼有。

临床怎么用

  • 作者认为基于胶囊海绵的监测或可用于低风险巴雷特食管以替代内镜。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic surveillance is the clinical standard for Barrett's oesophagus, but its effectiveness is inconsistent. We have developed a test comprising a pan-oesophageal cell collection device coupled with biomarkers to stratify patients into three risk groups. We aimed to prospectively evaluate the prespecified risk stratification tool to establish whether it can identify those at highest risk of dysplasia or cancer to prioritise the timing of endoscopy; and safely be used to follow up the low-risk group, thus sparing patients from unnecessary endoscopies. METHODS: Participants were recruited as part of two multicentre, prospective, pragmatic implementation studies from 13 hospitals in the UK. Patients with non-dysplastic Barrett's oesophagus had a capsule-sponge test which was assessed in an ISO-accredited laboratory. Patients were included if they were aged at least 18 years with a non-dysplastic Barrett's oesophagus diagnosis at their last endoscopy who were undergoing surveillance according to the published UK guidelines. Patients were assigned as low (clinical and capsule-sponge biomarkers negative), moderate (negative for capsule-sponge biomarkers, positive clinical biomarkers-age, sex, and segment length), or high risk (p53 abnormality or glandular atypia regardless of clinical biomarkers, or both). The primary outcome was a diagnosis of high-grade dysplasia or cancer necessitating treatment, according to the risk group assignment. FINDINGS: 910 patients recruited between August, 2020, and December, 2024 participated, of whom 138 (15%) were classified as high risk, 283 (31%) moderate risk and 489 (54%) low risk. The positive predictive value for any dysplasia or worse in the high-risk group was 37·7% (95% CI 29·7-46·4). Patients with both atypia and aberrant p53 had the highest risk of high-grade dysplasia or cancer (relative risk 135·8 [95% CI 32·7-564·0] relative to the low-risk group). The prevalence of high-grade dysplasia or cancer in the low-risk group was 0·4% (95% CI 0·1-1·6); the negative predictive value for any dysplasia or cancer was 97·8% (95% CI 95·9-98·8). Applying a machine learning algorithm as part of a digital-pathology workflow reduces the proportion needing p53 pathology review to 32% without missing any positive cases. INTERPRETATION: The risk-panel substantially enriches for dysplasia and capsule-sponge-based surveillance could be used in low-risk Barrett's oesophagus in lieu of endoscopy. FUNDING: Innovate UK, Cancer Research UK, National Health Service England Cancer Alliance.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Tan WK, Ross-Innes CS, Somerset T, et al. Biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation. Lancet. 2025. PMID: 40570865. doi:10.1016/S0140-6736(25)01021-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。